When used alongside acetylsalicylic acid, cangrelor is indicated for reducing the risk of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing PCI, who have not received an oral P2Y12 inhibitor before the PCI procedure, and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable [11]. The gene discussed is P2RY12; the disease is coronary artery disorder.